Antibody-Mediated p53 Protein Therapy Prevents Liver MetastasisIn vivo
Open Access
- 15 February 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (4) , 1769-1774
Abstract
To evaluate the clinical efficacy of monoclonal antibody (mAb) 3E10 Fv antibody-mediated p53 protein therapy, an Fv-p53 fusion protein produced in Pichia pastoris was tested on CT26.CL25 colon cancer cells in vitro and in vivo in a mouse model of colon cancer metastasis to the liver. In vitro experiments showed killing of CT26.CL25 cells by Fv-p53 but not Fv or p53 alone, and immunohistochemical staining confirmed that Fv was required for transport of p53 into cells. Prevention of liver metastasis in vivo was tested by splenic injection of 100 nmol/L Fv-p53 10 min and 1 week after injection of CT26.CL25 cancer cells into the portal vein of BALB/c mice. Mice were sacrificed 1 week after the second injection of Fv-p53 and assigned a quantitative metastasis score. Control mice had an average metastasis score of 3.3 ± 1.3, whereas mice treated with Fv-p53 had an average metastasis score of 0.8 ± 0.4 (P = 0.004). These results indicate that Fv-p53 treatment had a profound effect on liver metastasis and represent the first demonstration of effective full-length p53 protein therapy in vivo. mAb 3E10 Fv has significant clinical potential as a mediator of intracellular and intranuclear delivery of p53 for prevention and treatment of cancer metastasis. [Cancer Res 2007;67(4):1769–74]Keywords
This publication has 16 references indexed in Scilit:
- Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trialsExpert Opinion on Biological Therapy, 2006
- The Features and Shortcomings for Gene Delivery of Current Non-Viral CarriersCurrent Medicinal Chemistry, 2006
- A mouse model for developing treatment for secondary liver tumorsInternational Journal of Oncology, 2005
- Selectively increasing inducible heat shock protein 70 via TAT‐protein transduction protects neurons from nitrosative stress and excitotoxicityJournal of Neurochemistry, 2005
- Mouse Models of Subcutaneous Spleen Reservoir for Multiple Portal Venous Injections to Treat Liver MalignanciesCancer Research, 2005
- Antibody-mediated transduction of p53 selectively kills cancer cells.International Journal of Oncology, 2004
- HIV-1 tat protein upregulates inflammatory mediators and induces monocyte invasion into the brainMolecular and Cellular Neuroscience, 2003
- HIV Tat Peptide Enhances Cellular Delivery of Antisense Morpholino OligomersAntisense and Nucleic Acid Drug Development, 2003
- p53Cell, 2000
- Epitope-specific tolerance induction with an engineered immunoglobulin.Proceedings of the National Academy of Sciences, 1996